Galectin Therapeutics Q1 Loss Widens - Quick Facts

(RTTNews) - Galectin Therapeutics Inc. (GALT) posted first-quarter net loss applicable to common stock of $5.4 million or $0.27 per share, wider than $3.5 million or $0.22 per share in the prior year period. The increase in net loss applicable to common stock in the quarter ended March 31, 2014 over 2013 is primarily due to an increase in pre-clinical and clinical development expenses and an increase in non-cash stock-based compensation expense.

Analysts polled by Thomson Reuters expected the company to report a loss of $0.20 per share.

Total operating loss for the quarter was $4.8 million, wider than $3.2 million last year.